

A practical guide for providers on helping patients find Aurovela Fe 1/20 in stock, including 5 actionable steps, alternatives, and workflow tips.
You've probably heard it from your patients more than once this year: "My pharmacy says Aurovela Fe 1/20 is out of stock." Maybe they've called your office asking for a new prescription, or they've shown up anxious because they haven't been able to take their pill for several days.
As a provider, you can't control the pharmaceutical supply chain. But there are concrete steps you can take to minimize disruptions for your patients and keep them on continuous contraceptive coverage. This guide lays out a practical approach.
Aurovela Fe 1/20 (Norethindrone Acetate 1 mg / Ethinyl Estradiol 20 mcg / Ferrous Fumarate 75 mg) is manufactured by Aurobindo Pharma and remains on the market. It is not listed on the FDA Drug Shortage Database as of March 2026.
However, pharmacy-level availability has been inconsistent. The issue is driven by:
Other generics in this class — Junel Fe 1/20, Microgestin Fe 1/20, Blisovi Fe 1/20, and Larin Fe 1/20 — may be more readily available depending on location and pharmacy.
Understanding the root causes helps frame your response to patients:
Aurobindo Pharma is actively producing Aurovela Fe 1/20. The bottleneck is between manufacturer and pharmacy shelf. Large chain pharmacies order from a single primary distributor, and that distributor decides how to allocate limited inventory. If your patient's local CVS or Walgreens doesn't receive a shipment, the pills aren't there — even though they exist in the supply chain.
Pharmacy chains regularly renegotiate their generic contracts. A pharmacy that carried Aurovela Fe 1/20 last month might now stock Junel Fe 1/20 instead. The patient shows up, and their specific brand isn't there. If the prescription was written with DAW for Aurovela, the pharmacist can't legally dispense the available equivalent without contacting you.
Many patients believe their specific brand is uniquely important and may be reluctant to accept a substitution. Proactive education about bioequivalence can prevent this from becoming a barrier.
Whenever clinically appropriate, prescribe by generic name: Norethindrone Acetate / Ethinyl Estradiol 1 mg / 20 mcg with Ferrous Fumarate 75 mg. This allows pharmacists to dispense whichever AB-rated generic they have in stock — Aurovela, Junel, Microgestin, Blisovi, or Larin — without needing to call your office for authorization.
Review your prescribing habits. If you've been writing DAW for specific generics out of habit rather than clinical necessity, consider removing the restriction. There are no clinically meaningful differences between the AB-rated generics of Loestrin Fe 1/20. Removing DAW gives your patients the best chance of filling their prescription on the first try.
Take 30 seconds during the visit to tell patients: "There are several brands of this exact same medication. If your pharmacy has a different brand than usual, it's safe to switch. They all have the same active ingredients at the same doses." This simple conversation can save patients days of anxiety and phone calls when their pharmacy offers a different generic.
When a patient calls to report a stock-out, have your staff check Medfinder for Providers. It takes less than a minute to search for Aurovela Fe 1/20 (or any generic equivalent) and identify pharmacies near the patient that have it available. You can then direct the patient — or transfer the prescription — to a pharmacy with stock.
If your patient's insurance allows it, prescribing a 90-day supply (through mail-order or retail) reduces the number of times they need to navigate the refill process. Fewer refills means fewer opportunities for a stock-out to disrupt their care.
When Aurovela Fe 1/20 specifically is unavailable, the following are direct therapeutic equivalents:
For patients who might benefit from a different formulation entirely:
For a comprehensive review of options, see our clinical alternatives post: Alternatives to Aurovela Fe 1/20.
Here are some practical workflow adjustments that can reduce the burden on your staff and improve patient outcomes:
Develop a simple protocol for when patients call about stock-outs:
Once a quarter, review your active OC prescriptions for DAW designations that may no longer be necessary. This proactive step can prevent future patient calls.
During annual well-woman visits or contraceptive counseling appointments, mention that supply variability is common and that multiple equivalent brands exist. Setting expectations upfront reduces patient anxiety when they encounter a stock-out.
Keep a list of equivalent generics and their manufacturers posted in your prescribing area or embedded in your EHR as a favorite. This makes it easy to switch prescriptions quickly when a patient reports availability issues.
The inconsistent availability of Aurovela Fe 1/20 is frustrating for patients and adds administrative burden to your practice. But with flexible prescribing habits, proactive patient education, and tools like Medfinder for Providers, you can significantly reduce the impact on your patients' care.
The single most impactful change: write prescriptions generically and remove unnecessary DAW designations. This one step gives pharmacists the flexibility to keep your patients on their medication without a single phone call to your office.
For more supply and shortage context, see our provider shortage briefing. For cost-related guidance to share with patients, see how to help patients save money on Aurovela Fe 1/20.
You focus on staying healthy. We'll handle the rest.
Try Medfinder Concierge FreeMedfinder's mission is to ensure every patient gets access to the medications they need. We believe this begins with trustworthy information. Our core values guide everything we do, including the standards that shape the accuracy, transparency, and quality of our content. We’re committed to delivering information that’s evidence-based, regularly updated, and easy to understand. For more details on our editorial process, see here.